TB-500 (5 mg Vial) Dosage Protocol

Plan based on an 8–16 week daily protocol with gradual titration.

• Peptide Vials (TB‑500, 5 mg each):
  • 8 weeks: approximately 8 vials required
  • 12 weeks: approximately 12 vials required
  • 16 weeks: approximately 16 vials required
• Insulin Syringes (U‑100):
  • Per week: 7 syringes (1/day)
  • 8 weeks: 56 syringes
  • 12 weeks: 84 syringes
  • 16 weeks: 112 syringes
• Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
  • 8 weeks (8 vials): 24 mL — 3 bottles required (10 mL each)
  • 12 weeks (12 vials): 36 mL — 4 bottles required (10 mL each)
  • 16 weeks (16 vials): 48 mL — 5 bottles required (10 mL each)
• Alcohol Swabs: One for the vial stopper + one for the injection site each day.
  • Per week: 14 swabs (2/day)
  • 8 weeks: 112 swabs — 2 boxes required (100 swabs each)
  • 12 weeks: 168 swabs — 2 boxes required (100 swabs each)
  • 16 weeks: 224 swabs — 3 boxes required (100 swabs each)

TB-500 5 mg

View Supplier

U-100 syringes

View Supplier

Bacteriostatic water

View Supplier

Alcohol swabs

View Supplier

Practice preparing this vial with the verified strength and final volume from this protocol.

• Reconstitute: Add 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration.
• Typical daily range: 500–1000 mcg once daily (gradual titration recommended).
• Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 mcg on a U‑100 insulin syringe.
• Storage: Lyophilized: store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); do not freeze reconstituted solution.

TB‑500 is a synthetic peptide fragment corresponding to the active region of thymosin beta‑4 (Tβ4), a naturally occurring 43‑amino‑acid protein involved in tissue repair and regeneration^[1][2]. This educational protocol presents a once‑daily subcutaneous approach using a practical dilution for accurate insulin‑syringe measurements in research settings.

This TB-500 5 mg dosage protocol explains the exact 3 mL reconstitution math, 1.67 mg/mL vial concentration, and U-100 syringe conversions used by the established chart. It also distinguishes Ac-LKKTETQ from the full-length 43-amino-acid thymosin beta-4 studied in much of the human literature^[1][2].

Concise summary of the once‑daily regimen.

• Goal: Support tissue repair, wound healing, and angiogenesis through the active thymosin beta‑4 fragment mechanism^[5][6].
• Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if research goals require).
• Dose Range: 500–1000 mcg daily with gradual titration (~5 mg/week average).
• Reconstitution: 3.0 mL per 5 mg vial (~1.67 mg/mL) for accurate unit measurements.
• Storage: Lyophilized frozen; reconstituted refrigerated; avoid freeze–thaw cycles of reconstituted solution.

Suggested daily titration approach.

• Start: 500 mcg daily; increase by ~100–150 mcg every 2 weeks as tolerated.
• Target: 750–1000 mcg daily by Weeks 5–12.
• Frequency: Once per day (subcutaneous).
• Cycle Length: 8–12 weeks; optional extension to 16 weeks based on research protocol.
• Timing: Any consistent time daily; rotate injection sites systematically.

The supplier record describes the unopened 5 mg material as a lyophilized powder stored at -20 degrees C. It does not publish a product-specific reconstituted stability or discard period^[17].

• Lyophilized vial: Follow the product label and batch documentation for storage.
• Prepared vial: Keep the established 2-8 degrees C page instruction, protect the vial from light, and do not infer a universal use-by period.
• Label: Record compound, 1.67 mg/mL concentration, preparation date, lot number, and storage conditions.
• Handling: Minimize unnecessary warming, agitation, and repeated temperature changes.

This TB-500 5 mg dosage page uses a 5 mg vial and a 3.0 mL final volume. For this TB-500 reconstitution, 5 mg divided by 3.0 mL equals 1.6667 mg/mL, or approximately 1,667 mcg/mL. The calculation is independent of the biological evidence.

• Per 0.01 mL U-100 unit: approximately 16.7 mcg.
• 30 units: 0.30 mL and approximately 500 mcg.
• 36 units: 0.36 mL and approximately 600 mcg.
• 45 units: 0.45 mL and approximately 750 mcg.
• 60 units: 0.60 mL and approximately 1,000 mcg.

These values explain the locked table mathematically. They do not establish that the schedule has been validated in human research.

TB-500 is described in analytical literature as the N-terminally acetylated heptapeptide Ac-LKKTETQ, corresponding to residues 17-23 of thymosin beta-4^[1][2]. That identity is not interchangeable with the complete 43-amino-acid thymosin beta-4 protein.

The LKKTETQ region overlaps the central actin-binding domain studied for cell migration, angiogenesis, extracellular-matrix remodeling, and wound-repair signaling^[4][5]. A 2024 metabolism study reported that the parent TB-500 fragment and several metabolites behaved differently in a fibroblast scratch assay; the authors found significant wound-closure activity for one metabolite rather than the parent compound^[3].

The approved supplier page identifies a 5 mg lyophilized research vial and provides a batch-specific certificate summary. That page supports product labeling and provenance, not a clinical dosing claim^[17].

Human research often cited in this area studied full-length thymosin beta-4, recombinant thymosin beta-4, or topical ophthalmic formulations. It did not test this 5 mg Ac-LKKTETQ vial or the schedule shown in the primary chart.

• Two phase 1 studies examined intravenous full-length or recombinant thymosin beta-4 in healthy volunteers, using formulations and dose units that do not validate a subcutaneous TB-500 fragment protocol^[10][11].
• Small ophthalmic trials evaluated 0.1% full-length thymosin beta-4 eye drops. One severe dry-eye study reported improvements, while a larger controlled-environment study missed both primary endpoints and reported differences in selected secondary outcomes^[12][13].
• Preclinical studies of full-length thymosin beta-4 or the LKKTETQ domain reported wound-repair, cell-migration, matrix-remodeling, or angiogenesis findings in animal and cell models^[5][6][7].
• FDA states that it has not identified human exposure data for thymosin beta-4 fragment (LKKTETQ), also known as TB-500, and that available information is insufficient to determine whether compounded use would cause harm^[14].

The page’s established chart is therefore a research calculation schedule, not a human clinical standard, treatment recommendation, or conclusion drawn from the full-length thymosin beta-4 trials.

Searches for TB-500 dosing often connect the peptide with tendon, ligament, muscle injury, tissue healing, or injury recovery. The cited literature does not establish a human TB-500 dosage for those outcomes. Preclinical findings involving full-length thymosin beta-4 or related sequences should not be presented as proof that this fragment accelerates healing in people.

A responsible TB-500 protocol guide must separate vial arithmetic from biological claims. This page therefore preserves the established dosing schedule for calculation consistency while clearly identifying the absence of validating human TB-500 fragment trials.

Full-length thymosin beta-4 binds monomeric actin and helps regulate the balance between actin sequestration and filament assembly. Reviews connect those cytoskeletal effects with cell motility, differentiation, tissue repair, angiogenesis, and organ-specific experimental models^[8][9].

The smaller LKKTETQ sequence has been studied as an active region within the parent protein. Experimental reports associate that domain with matrix metalloproteinase expression, keratinocyte or endothelial migration, collagen deposition, and wound closure in preclinical models^[4][5][7].

Fragment identity still matters. Results from full-length thymosin beta-4, unacetylated LKKTETQ, acetylated Ac-LKKTETQ, and TB-500 metabolites should not be merged into one clinical claim. The molecule, formulation, route, and experimental model must match the statement being made^[1][3].

• Human safety gap: FDA reports no identified human exposure data for the TB-500 fragment and notes potential immunogenicity concerns related to aggregation and peptide-related impurities for certain routes^[14].
• Formulation gap: Human thymosin beta-4 studies used different molecules, formulations, routes, and research questions. Their tolerability findings cannot be transferred to this vial^[10][12].
• Preclinical ceiling: Cell and animal findings can identify mechanisms and research questions, but they do not establish efficacy, safety, or a dosage recommendation for humans.
• Sport: The 2026 World Anti-Doping Agency Prohibited List names thymosin beta-4 and TB-500 among prohibited growth factors and growth-factor modulators^[15].
• Batch identity: A supplier certificate is a lot-specific analytical record. It does not transform a research material into an approved drug or validate the schedule on this page^[17].

The primary table uses U-100 syringe markings as volume measurements. One unit equals 0.01 mL; it is not an international unit of TB-500 activity.

• Use a new sterile syringe for each recorded administration and dispose of it in an approved sharps container.
• Clean the vial stopper and skin, then allow both surfaces to dry before the procedure.
• Measure the exact U-100 marking at eye level and check that the matching mL value agrees with the table.
• Use the institution’s approved subcutaneous-injection procedure for site selection, needle angle, administration, and site rotation^[16].
• Document date, time, vial lot, concentration, volume, syringe units, and observations in the research record.

What concentration does a TB-500 5 mg vial make with 3 mL?

Using the page’s established preparation, 5 mg divided by 3.0 mL equals about 1.67 mg/mL, or 1,667 mcg/mL. One U-100 unit, equal to 0.01 mL, therefore contains about 16.7 mcg.

Is TB-500 the same molecule as full-length thymosin beta-4?

No. Analytical papers identify TB-500 as Ac-LKKTETQ, an acetylated fragment associated with residues 17-23 of the complete thymosin beta-4 protein^[1][2].

Do human thymosin beta-4 trials validate this TB-500 dosage chart?

No. Published human studies used full-length or recombinant thymosin beta-4 and different routes, including intravenous and ophthalmic administration^{[10][11][12][13]}. They do not validate the Ac-LKKTETQ schedule on this page.

Why does the 5 mg vial need a separate page from the 10 mg vial?

The vial strength changes concentration, U-100 unit conversions, vial yield, and supply planning. The 5 mg page owns those exact-strength calculations while the family research overview covers broader TB-500 evidence.

How long is reconstituted TB-500 stable?

No universal post-reconstitution stability period is established by the product page or the cited fragment literature. Follow product-specific documentation and the applicable laboratory stability and sterile-handling plan rather than inferring a fixed discard date from refrigeration alone.

The dosage table is retained as the page’s established nonclinical calculation schedule. It is not an FDA-approved regimen, a medical recommendation, or a schedule established by human TB-500 fragment trials. Human findings from full-length thymosin beta-4 are not evidence that the same effects, safety, or amounts apply to Ac-LKKTETQ.

• 1
  Drug Testing and Analysis – Esposito et al. (2012), synthesis and characterization of the N-terminal acetylated thymosin beta-4 17-23 fragment identified in TB-500.

  View Source
• 2
  Journal of Chromatography A – Ho et al. (2012), analytical identification of N-acetylated LKKTETQ and metabolites after equine TB-500 administration.

  View Source
• 3
  Journal of Chromatography B – Rahaman et al. (2024), TB-500 metabolism and comparative fibroblast wound-healing activity of the parent fragment and metabolites.

  View Source
• 4
  FASEB Journal – Sosne et al. (2010), biological activities mapped to short thymosin beta-4 peptide sequences.

  View Source
• 5
  Journal of Cellular Physiology – Philp et al. (2006), thymosin beta-4, its central actin-binding domain, and matrix metalloproteinase expression in wound-repair models.

  View Source
• 6
  Journal of Investigative Dermatology – Malinda et al. (1999), full-length thymosin beta-4 in rat dermal wound-healing and cell-migration models.

  View Source
• 7
  Wound Repair and Regeneration – Philp et al. (2003), full-length thymosin beta-4 and LKKTETQ in diabetic and aged mouse wound-repair models.

  View Source
• 8
  Expert Opinion on Biological Therapy – Goldstein et al. (2012), review of full-length thymosin beta-4 biology and clinical research.

  View Source
• 9
  Current Protein and Peptide Science – Ying et al. (2023), review of thymosin beta-4 actin binding, functions, and clinical research.

  View Source
• 10
  Journal of Cellular and Molecular Medicine – Wang et al. (2021), phase 1 intravenous recombinant human thymosin beta-4 study in healthy volunteers.

  View Source
• 11
  Annals of the New York Academy of Sciences – Ruff et al. (2010), randomized single- and multiple-dose intravenous full-length thymosin beta-4 study in healthy volunteers.

  View Source
• 12
  Cornea – Sosne et al. (2015), small phase 2 randomized trial of 0.1% thymosin beta-4 ophthalmic solution for severe dry eye.

  View Source
• 13
  Clinical Ophthalmology – Sosne and Ousler (2015), phase 2 ophthalmic thymosin beta-4 trial that did not meet either primary endpoint and reported selected secondary findings.

  View Source
• 14
  U.S. Food and Drug Administration – Safety-risk summary for thymosin beta-4 fragment (LKKTETQ), also known as TB-500.

  View Source
• 15
  World Anti-Doping Agency – 2026 Prohibited List naming thymosin beta-4 and derivatives such as TB-500.

  View Source
• 16
  NCBI Bookshelf – Nursing Skills chapter on parenteral medication and subcutaneous injection procedures.

  View Source
• 17
  Pure Lab Peptides – TB-500 5 mg product record for label, vial format, supplier destination, and batch documentation context.

  View Source

Explore the available research context, protocol variants or comparisons, and practical guides. When vial-strength variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable.